Combined evaluation of IGF-1 and IGFBP-3 as an index of efficacy and safety in growth hormone treated patients

JCRPE Journal of Clinical Research in Pediatric Endocrinology

Volumn 1, Issue 5, 2009, Pages 240-243

  Şiklar, Zeynep ^a   Öcal, Gönül ^a   Berberoǧlu, Merih ^a   Bilir, Pelin ^a  

^a ANKARA UNIVERSITY   (Turkey)

Author keywords

Growth hormone therapy; IGF 1; IGFBP 3

Indexed keywords

GROWTH HORMONE; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; GROUPS BY AGE; GROWTH HORMONE DEFICIENCY; HUMAN; LONGITUDINAL STUDY; RELIABILITY;

BIOLOGICAL MARKERS; BODY HEIGHT; CHILD; GROWTH DISORDERS; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; LONGITUDINAL STUDIES; TREATMENT OUTCOME;

EID: 77953413371     PISSN: 13085727     EISSN: 13085735     Source Type: Journal    
DOI: 10.4274/jcrpe.v1i5.240     Document Type: Article

References (18)

1. Drake WM, Howell SJ, Monson JP, Shalet SM. Optimizing GH therapy in adults and children. Endocrine Reviews 2001;22: 425-450. [Abstract] / [Full Text] / [PDF]
2. GH Research Society. Consensus Guidelines for the diagnosis and treatment of growth hormone (GH) deficiency in childhood and adolescence: summary statement of the GH research society. J Clin Endocrinol Metab 2000; 85: 3990-3993. [Abstract] / [Full Text] / [PDF]
3. Cohen P, Franklin S, Rogol AD, Bright G, Rosenfeld RG. What is the optimal dose of ghowth hormone? Highlights 2000; 8: 1-18.
4. Giovannucci E. Insulin-like growth factor-1 (IGF-1) and IGF binding protein-3 (IGFBP-3) and risk of cancer. Horm Res 1999; 51: 34-41. [Abstract] / [Full Text] / [PDF]
5. Bereket A, Turan S, Omar A, Berber M, Ozen A, Akbenlioglu C, Haklar G. Serum IGF-1 and IGFBP-3 levels of Turkish children during childhood and adolescence: establishment of reference ranges with emphasis on puberty. Horm Res 2006; 65: 96-105. [Abstract] / [Full Text] / [PDF]
6. Tillmann V, Patel L, Gill MS, Whatmore AJ, Price DA, Kibirige MS, Wales JK, Clayton P. Monitoring serum insulin-like growth factor-1 (IGF-1), IGF binding protein-3 (IGFBP-3), IGF-1 / IGFBP-3 molar ratio and leptin during growth hormone treatment for growth. Clin Endocrinol 2000; 53: 329-336. [Abstract]
7. Ranke MB, Schweizer R, Elmlinger MW, Weber K, Binder G, Schwarze CP, Wollmann HA.Relevance of IGF-1, IGFBP-3, and IGFBP-2 measurements during GH treatment of GH-deficient and non-GH-deficient children and adolescents. Horm Res 2001; 55: 115-124. [Abstract] / [Full Text] / [PDF]
8. Shim M, Cohen P. IGFs and human cancer: implication regarding the risk of growth hormone therapy. Horm Res 1999; 51: 42-51. [Abstract] / [Full Text] / [PDF]
9. Khandwala HM, McCutcheon IE, Flyvbjerg A, Friend KE. The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocrine Reviews 2000; 21: 215-244. [Abstract] / [Full Text]
10. Ma J, Pollak MN, Giovannucci E, Chan JM, Tao Y, Hennekens CH, Stampfer MJ. Prospective study of colorectal cancer risk in men and plasma levels of insuline-like growth factor (IGF-1) and IGF-binding protein-3 (IGFBP-3). J Natl Cancer Inst 1999; 91: 620-625. [Abstract] / [Full Text] / [PDF]
11. Fürstenberger G, Senn HJ. Insuline-like growth factors and cancer. Lancet 2002; 3: 298-302. [Abstract] / [Full Text] / [PDF]
12. Wolk A, Mantzoros CS, Andersson SO, Bergström R, Signorello LB, Lagiou P, Adami HO, Trichopoulus D. Insuline-like growth factor-I and prostate cancer risk: a population-based, case-control study. J Natl Cancer Inst 1998; 90: 911-915. [Abstract]
13. Bohlke K, Cramer DW, Trichopoulus D, Mantzoros CS: Insuline-like growth factor-I in relation to premenaposal ductal carcinoma in situ of the breast. Epidemiology 1998; 9: 570-573. [Abstract] / [Full Text]
14. Freier S, Weiss O, Eran M, Flybjerg A, Dahan R, Nephesh I, Safra T, Shiloni E, Raz I. Expression of the Insuline-like growth factors and their receptors in adenocarcinoma of the colon. Gut 1999; 44: 704-708. [Abstract] / [Full Text] / [PDF]
15. Yu H, Spitz MR, Mistry J, Gu J, Hong WK, Wu X. Plasma levels of insuline-like growth factor-I and lung cancer risk: a case control analysis. J Natl Cancer Inst 1999; 91: 151-156. [Abstract] / [Full Text] / [PDF]
16. Cacciari E. GH treatment and risk for extracranial neoplasms. International Growth Monitor 2003; 5: 16-17.
17. Papagianni M, Stanhope R. Should serum IGF-1 concentrations be monitored routinely during growth hormone therapy? J Ped Endocrinol Metab 2004; 17: 141-142. [Abstract]
18. Skjaerbaek C, Vahl N, Frystyk J, Hansen TB, Jargensen JOL, Hagen C, Christiansen JS, Oiskov H. Serum free insulin-like growth factor-1 in growth hormone deficient adults before and after growth hormone replacement. Eur J Endocrinol 1997;137:132-137. [Abstract] / [PDF]